Metier Executives

Revolutionizing the Future of Robotic Surgery: Meet Ottava Johnson & Johnson MedTech #Ottava surgical robotic system is set to redefine robotic-assisted surgery. Ottava has long been discussed and was designed to address the challenges of today’s ORs with groundbreaking features that enhance efficiency, precision, and collaboration. ✨ Invisible Design: Robotic arms integrated directly into a standard surgical table. They’re there when you need them and out of the way when you don’t—providing surgeons and their teams more space to work and access to the patient. 🔄 Twin Motion Technology: Synchronizing the movement of four robotic arms and the surgical table. Surgeons can reposition during procedures without interrupting the workflow, perfect for complex, multi-quadrant surgeries. 🛠️ Custom Ethicon Instruments: Leveraging decades of laparoscopic innovation, Ottava offers consistency and reliability between traditional and robotic procedures. 💡 Latest Milestone: In November 2024, Ottava received FDA IDE approval, allowing clinical trials to begin in the U.S. This marks a pivotal step toward redefining surgical care. As Johnson & Johnson MedTech continues to prepare for clinical trials, Ottava stands ready to transform robotic surgery by empowering surgeons, improving patient outcomes, and optimizing the OR of the future. #SurgicalInnovation #RoboticSurgery #HealthcareTech #PatientCare #Innovation #JohnsonAndJohnson #Ottava

Medtronic acquires Fortimedix Surgical to boost surgical portfolio Fortimedix Surgical B.V. Surgicalportfolio of articulating instruments that can be used in endoscopic, minimally invasive, and robotic surgeries. The company notes that its robotic applications include multi-port and single-port soft tissue robotics, flexible robotics, and robotic endoscopic surgery. Medtronic has invested in developing its endoscopy portfolio. Last December, the medtech giant partnered with Cosmo Pharmaceuticals’s subsidiary, Cosmo Intelligent Medical Devices to integrate AI into its GI Genius intelligent endoscopy module. Medtronic also collaborated with NVIDIA to include AI in GI modules. https://lnkd.in/eG-tJD8k

🚀 Big News in Surgical Robotics! Johnson & Johnson has received FDA Investigational Device Exemption (IDE) approval to begin a clinical study of its innovative #Ottava surgical robotic system. This advancement is a huge milestone for both J&J and the broader field of robotic-assisted surgery, promising to bring greater precision, control, and outcomes to minimally invasive procedures. Ottava stands out for its unique four-arm system that allows surgeons to operate without needing to reposition tools mid-procedure. The increased control, coupled with advanced imaging and ergonomics, could redefine expectations in surgical robotics and improve the experience for both surgeons and patients. It’s an exciting step forward, especially as healthcare continues its journey towards enhanced patient outcomes and cost efficiencies. With this study, we’re on the brink of seeing how the Ottava could change the game in ORs around the world and making the recently announced dates of the end of the decade for launch. 🌐 #SurgicalRobotics #MedicalInnovation #PatientCare #JohnsonAndJohnson #Ottava #HealthcareTech https://lnkd.in/eSjCeGxW MassDevice Sean Whooley

GE HealthCare and RadNet are teaming up to push the boundaries of imaging technology! This collaboration is set to bring AI-driven advancements to imaging systems, aiming to improve patient outcomes, streamline workflows, and reduce costs across healthcare networks. Key highlights from this partnership include: 🔹 Enhanced Imaging Capabilities: RadNet and GE Healthcare will combine forces to develop smart imaging systems that leverage advanced AI to help radiologists detect and diagnose with greater accuracy and speed. 🔹 Workflow Optimization: Through integrating innovative software, the collaboration will empower healthcare providers to manage imaging data more efficiently, transforming how patient information is accessed and analyzed. 🔹 Better Patient Care: With this technology, providers can detect health issues earlier, helping lead to better health outcomes and more personalized patient care. By accelerating the adoption of #AI in medical imaging, GE Healthcare and RadNet are setting a new standard for healthcare technology. Together, they’re redefining what’s possible in radiology, benefiting both healthcare providers and patients. This is a huge step forward for smart technology in healthcare! #HealthcareInnovation #ArtificialIntelligence #MedicalImaging #Radiology #PatientCare #GEHealthcare #RadNet #FutureOfHealth https://lnkd.in/ePqN6-Px

Global Developments in PROCEPT BioRobotics: Q3 2024 Financial Results PROCEPT BioRobotics continued its strong performance in the third quarter of 2024, reflecting a clear focus on innovation and global expansion in urological care. The Q3 earnings noted a better than expected performance in EPS and Gross Margin which indicates the company could be FCF (Free Cash Flow) earlier than expected. Q3 Earnings Key Highlights: > Total revenue of $58.4 million, marking a 66% year-over-year growth. > Sold 52 robotic systems in the U.S. during the quarter. > 80% of the systems sold in the US were the new HYDROS AI Robotic System > International revenue contributed significantly, reflecting growing demand > Revised full-year 2024 guidance to $222.5-$223.0 million, an upward revision driven by increasing market adoption and strong execution. 🌍 International Growth: PROCEPT’s global reach continues to expand, with increasing traction across key international markets, bolstering revenue growth. 📈 Financial Strength: The company’s substantial revenue increase and raised guidance indicate a clear path towards solidifying its position in the urology robotics market. We are continuing to support Procept's Commercial, Clinical and Marketing team recruitment across International reach out to Metier Executives for more information. #roboticsurgery #medtech

Intuitive Surgical has once again demonstrated its market leadership with impressive Q3 2024 results. The company reported $2.04 billion in revenue, a 17% year-over-year increase, outperforming analyst expectations of $2 billion. Adjusted earnings per share (EPS) came in strong at $1.84, significantly beating the forecast of $1.63. Key to this success was the continued growth in da Vinci robotic-assisted surgeries, with procedures increasing by 18% compared to the same period last year. The company also saw a surge in system placements, selling 379 da Vinci systems, including 110 units of the latest da Vinci 5, marking a notable jump from the 312 systems sold in Q3 2023. This quarter also marked a milestone for Intuitive Surgical’s installed base, which now totals 9,539 systems globally, reflecting a 15% growth year-over-year. The company is well-positioned financially, with its cash and equivalents reaching $8.31 billion, an increase of $628 million from the previous quarter. These results underscore Intuitive Surgical’s strong market demand and its successful execution of growth strategies, driven by innovation in robotic-assisted surgery and a focus on improving patient outcomes. As the healthcare landscape evolves, Intuitive Surgical remains a key player in transforming surgery.

CMR Surgical obtained a de novo clearance from the FDA for its #Versius surgical system, allowing its modular, cart-based, laparoscopic robotic system to be accessed in US. Versius is approved for Gall Bladder removal, a disease that is one of the most common procedures done in the United States with more than 1.2 million cholecystectomies treated annually. Versius previously received a CE Mark approval in Europe in early 2019 and has completed an estimated 26,000 procedures globally. #surgicalrobotics #medtech

PROCEPT BioRobotics® Corporation, an AI surgical robotics company announced the U.S. Food and Drug Administration (FDA) has approved a pivotal Investigational Device Exemption (IDE) clinical trial comparing Aquablation therapy to radical prostatectomy. The global prostate cancer market is substantial and continues to grow rapidly. In 2024, the market size is expected to reach around $13.7 billion, with projections suggesting it could expand to $30.3 billion by 2033, growing at a 9.2% compound annual growth rate (CAGR). The expansion of prostate cancer treatments, such as targeted therapies and minimally invasive surgical options, potentially like Aquablation, will further contribute to the growth of this market allowing more men to be treated earlier and more effectively. #medtech #surgicalrobotics https://lnkd.in/eFCTzt5Z

What is Senhance Surgical Robotics? Senhance Surgical Robotics, developed by Asensus Surgical now owned by KARL STORZ is transforming the future of minimally invasive surgery. Designed to give surgeons greater control while integrating cutting-edge technologies, Senhance combines the precision of robotics with the efficiency of digital laparoscopy. With features like haptic feedback, eye-tracking camera control, and reusable instruments, the system offers a unique blend of innovation and cost-effectiveness that sets it apart from traditional robotic platforms. The technology behind Senhance is focused on enhancing surgeon capabilities while reducing costs. Its haptic feedback provides a sense of touch during surgery, a critical feature for precision. Additionally, eye-tracking camera control allows for hands-free vision adjustment, boosting operational efficiency. With digital laparoscopy and 3D high-definition vision, surgeons experience enhanced depth perception and accuracy in every procedure. Senhance is not only about better technology, but it’s also about improving patient outcomes and making robotic surgery more accessible. By providing a cost-effective solution with reusable instruments and scalable capabilities, it empowers hospitals to adopt advanced surgical robotics without excessive costs. Senhance is redefining the standards of robotic-assisted surgery, paving the way for more efficient and precise operations. #surgicalrobotics #medtech

Key innovations in Urology for 2024 Great article by MassDevice's Sean Whooley on some of the leading innovations and updates we've seen in the Urology space already in 2024: 1. UroMems’ $47M raise for its smart urinary sphincter 2. Axonics, Inc.’ IP victory and Boston Scientific acquisition 3. PROCEPT BioRobotics’ FDA clearance for the #Hydros surgical robot 4. Medtronic launched the next-gen GI Genius endoscopy system 5. Olympus Medical Systems EMEA expanded with its #RenaFlex ureteroscope and 4K camera. 6. GE HealthCare released #AI software for prostate imaging 7. Biobot Surgical secured $18M for its Mona Lisa robotic system. Check out the full article: https://lnkd.in/escJrR8w